As part of newly announced collaborations with Cleveland-based Viewray Inc., Elekta AB assumed a 9.9% stake in the company, and Medtronic plc also made a minority investment. The company's largest shareholder, Fosun International Ltd., also led the round. "In total, the company raised approximately $139 million, net of fees," Viewray President and CEO Scott Drake told BioWorld MedTech.
The Chapel Hill, N.C.-based non-profit Digital Health Institute for Transformation (DHIT) and Tanjo Inc., a machine learning company headquartered in Carrboro, N.C., will launch their Community Health Utility Grid (HUG) Initiative in North Carolina in early 2020. The collaboration aims to improve healthcare outcomes for underserved populations in the state by collecting, analyzing, and sharing individual, household and community level health data.
Proteus Digital Health Inc.’s digital medicine program, Digimeds, achieved 95% adherence in patients with hepatitis C virus (HCV) who typically would not be offered direct acting antivirals because of their high risk for nonadherence as a result of mental illness, transportation issues or previous evidence of nonadherence.
Proteus Digital Health Inc.’s digital medicine program, Digimeds, achieved 95% adherence in patients with hepatitis C virus (HCV) who typically would not be offered direct-acting antivirals because of their high risk for nonadherence as a result of mental illness, transportation issues or previous evidence of nonadherence.
Hafnium nanoparticles that home onto microfractures in bone make the tiny cracks visible in spectral or color computed tomography (CT) imaging. Researchers at the University of Illinois at Urbana-Champaign and the University of Maryland created the nanotechnology to work in conjunction with spectral molecular imaging developed by New Zealand-based MARS Bioimaging Ltd. (MBI). The research appeared in Advanced Functional Materials.
A team led by researchers at Washington State University (WSU) has developed a nanoparticle technology to deliver cell-killing drugs to shut down the overactive immune response that can cause damage or death in diseases like stroke and sepsis without affecting other cell types or compromising the immune system.
A team led by researchers at Washington State University (WSU) has developed a nanoparticle technology to deliver cell-killing drugs to shut down the overactive immune response that can cause damage or death in diseases like stroke and sepsis without affecting other cell types or compromising the immune system.
Optina Diagnostics, of Montreal, and the Wagner Macula & Retina Center are collaborating on a clinical study using Optina's Retinal Deep Phenotyping (RDP) platform to screen for Alzheimer's disease. The program will put the platform into nine community eye clinics in Virginia and North Carolina.
The Alfred Mann Foundation (AMF) and Össur have signed an agreement that will allow Reykjavik, Iceland-based Össur to further develop and license the implanted myoelectric sensor (IMES) system developed by AMF. Both organizations expect clinical trials to begin within the year.
A JAMA Open Network study found that RNA testing determined whether 88% of variants of uncertain significance found in DNA testing for hereditary cancer genes were pathogenic or benign.